Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

The Use of Remdesivir in Patients with COVID-19

Author(s): Zeinab Mohseni Afshar, Dariush Hosseinzadeh, Rezvan Hosseinzadeh, Arefeh Babazadeh, Amirreza Allahgholipour, Terence T. Sio, Mark J. M. Sullman, Kristin Carson-Chahhoud, Mohammad Barary* and Soheil Ebrahimpour*

Volume 23, Issue 7, 2023

Published on: 23 June, 2023

Article ID: e090523216697 Pages: 13

DOI: 10.2174/1871526523666230509110907

Price: $65

conference banner
Abstract

Remdesivir has appeared to be the most effective medication against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and is broadly administered to coronavirus disease 2019 (COVID-19) patients around the world. Remdesivir is an RNA polymerase inhibitor with a broad spectrum of antiviral activities against RNA viruses in in-vitro and in-vivo models of SARSCoV, the Middle East respiratory syndrome (MERS), and SARS-CoV-2. Remdesivir is the first Food and Drug Administration (FDA) approved anti-SARS-CoV-2 treatment for adult and pediatric patients and has been used for not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death. However, questions have been raised about the value of remdesivir in treating COVID-19, and governing bodies worldwide have been hesitant to approve this medication. Nevertheless, in the context of the public health emergency and the urgent need for effective treatments for patients with COVID-19, remdesivir has been approved by several authorities worldwide. Here, we discuss the characteristics and applications of remdesivir, and various challenging studies with different outcomes about its efficacy are also reviewed.

[1]
Chera A, Tanca A. Remdesivir: The first FDA-approved anti-COVID-19 treatment for young children. Discoveries (Craiova) 2022; 10(2)e151
[PMID: 36156901]
[2]
Lin HXJ, Cho S, Meyyur Aravamudan V, et al. Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: A review of evidence. Infection 2021; 49(3): 401-10.
[http://dx.doi.org/10.1007/s15010-020-01557-7] [PMID: 33389708]
[3]
Malin JJ, Suárez I, Priesner V, Fätkenheuer G, Rybniker J. Remdesivir against COVID-19 and Other Viral Diseases. Clin Microbiol Rev 2020; 34(1): e00162-20.
[http://dx.doi.org/10.1128/CMR.00162-20] [PMID: 33055231]
[4]
Afshar ZM, Babazadeh A, Javanian M, Barary M, Rekha VVK, Ebrahimpour S. A comprehensive review of COVID-19 treatment. Acta facultatis medicae Naissensis 2021; 38(2): 105-15.
[5]
Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe COVID-19. N Engl J Med 2020; 382(24): 2327-36.
[http://dx.doi.org/10.1056/NEJMoa2007016] [PMID: 32275812]
[6]
Antinori S, Cossu MV, Ridolfo AL, et al. Compassionate remdesivir treatment of severe COVID-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status. Pharmacol Res 2020; 158104899
[http://dx.doi.org/10.1016/j.phrs.2020.104899] [PMID: 32407959]
[7]
Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395(10236): 1569-78.
[http://dx.doi.org/10.1016/S0140-6736(20)31022-9] [PMID: 32423584]
[8]
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of COVID-19 - final report. N Engl J Med 2020; 383(19): 1813-26.
[http://dx.doi.org/10.1056/NEJMoa2007764] [PMID: 32445440]
[9]
Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe COVID-19. N Engl J Med 2020; 383(19): 1827-37.
[http://dx.doi.org/10.1056/NEJMoa2015301] [PMID: 32459919]
[10]
Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19. JAMA 2020; 324(11): 1048-57.
[http://dx.doi.org/10.1001/jama.2020.16349] [PMID: 32821939]
[11]
Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe COVID-19 in outpatients. N Engl J Med 2022; 386(4): 305-15.
[http://dx.doi.org/10.1056/NEJMoa2116846] [PMID: 34937145]
[12]
WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: Final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet 2022; 399(10339): 1941-53.
[http://dx.doi.org/10.1016/S0140-6736(22)00519-0] [PMID: 35512728]
[13]
IFN-beta 1b and remdesivir for COVID19. Available from: https://ClinicalTrials.gov/show/NCT04647695
[14]
Comparison of remdesivir versus lopinavir/ ritonavir and remdesivir combination in COVID-19 patients. Available from: https://ClinicalTrials.gov/show/NCT04738045
[15]
Efficacy of ramdicivir and baricitinib for the treatment of severe COVID 19 Patients. Available from: https://ClinicalTrials.gov/show/ NCT04693026
[16]
Baricitinib in hospitalized COVID-19 patients with diabetes mellitus. Available from: https://ClinicalTrials.gov/show/NCT04970719
[17]
Remdesivir in COVID-19 lahore general hospital. Available from: https://ClinicalTrials.gov/show/NCT04560231
[18]
Clinical protocol for convalescent plasma and remdesivir therapy in Nepal. Available from: https://ClinicalTrials.gov/show/NCT04570982
[19]
Safety of remdesivir treatment in COVID-19 patients requiring hemodialysis. Available from: https://ClinicalTrials.gov/show/NCT04854837
[20]
Efficacy and safety of DWJ1248 With remdesivir in severe COVID-19 patients. Available from: https://ClinicalTrials.gov/show/NCT04713176
[21]
Study to evaluate the clinical outcomes in adults with COVID-19 who have been treated with remdesivir. Available from: https://ClinicalTrials.gov/show/NCT04847622
[22]
SOLIDARITY finland long COVID-19. Available from: https://ClinicalTrials.gov/show/NCT04978259
[23]
Tchesnokov E, Feng J, Porter D, Götte M. Mechanism of inhibition of ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses 2019; 11(4): 326.
[http://dx.doi.org/10.3390/v11040326] [PMID: 30987343]
[24]
Lo MK, Jordan R, Arvey A, et al. GS-5734 and its parent nucleoside analog inhibit filo-, pneumo-, and paramyxoviruses. Sci Rep 2017; 7(1): 43395.
[http://dx.doi.org/10.1038/srep43395] [PMID: 28262699]
[25]
Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017; 9(396)eaal3653
[http://dx.doi.org/10.1126/scitranslmed.aal3653] [PMID: 28659436]
[26]
Sheahan TP, Sims AC, Zhou S, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med 2020; 12(541)eabb5883
[http://dx.doi.org/10.1126/scitranslmed.abb5883] [PMID: 32253226]
[27]
Ferner RE, Aronson JK. Remdesivir in COVID-19. BMJ 2020; 369: m1610.
[http://dx.doi.org/10.1136/bmj.m1610] [PMID: 32321732]
[28]
Scavone C, Brusco S, Bertini M, et al. Current pharmacological treatments for COVID‐19: What’s next? Br J Pharmacol 2020; 177(21): 4813-24.
[http://dx.doi.org/10.1111/bph.15072] [PMID: 32329520]
[29]
Kokic G, Hillen HS, Tegunov D, et al. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nat Commun 2021; 12(1): 279.
[http://dx.doi.org/10.1038/s41467-020-20542-0] [PMID: 33436624]
[30]
Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem 2020; 295(20): 6785-97.
[http://dx.doi.org/10.1074/jbc.RA120.013679] [PMID: 32284326]
[31]
Lo MK, Feldmann F, Gary JM, et al. Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Sci Transl Med 2019; 11(494)eaau9242
[http://dx.doi.org/10.1126/scitranslmed.aau9242] [PMID: 31142680]
[32]
Dosing of remdesivir. Available from: https://www.vekluryhcp.com/dosing-and-admin/
[33]
Dölken L, Stich A, Spinner CD. Remdesivir for early COVID-19 treatment of high-risk individuals prior to or at early disease onset—lessons learned. Viruses 2021; 13(6): 963.
[http://dx.doi.org/10.3390/v13060963] [PMID: 34067381]
[34]
Wong CKH, Lau KTK, Au ICH, Xiong X, Lau EHY, Cowling BJ. Clinical improvement, outcomes, antiviral activity, and costs associated with early treatment with remdesivir for patients with COVID-19. Clin Infect Dis 2022; 74(8): 1450-8.
[PMID: 34265054]
[35]
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of COVID-19. N Engl J Med 2020; 383(19): 1813-26.
[http://dx.doi.org/10.1056/NEJMoa2007764] [PMID: 32445440]
[36]
Rezagholizadeh A, Khiali S, Sarbakhsh P, Entezari-Maleki T. Remdesivir for treatment of COVID-19: An updated systematic review and meta-analysis. Eur J Pharmacol 2021; 897173926
[http://dx.doi.org/10.1016/j.ejphar.2021.173926] [PMID: 33549577]
[37]
Singh AK, Singh A, Singh R, Misra A. Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies. Diabetes Metab Syndr 2020; 14(4): 641-8.
[http://dx.doi.org/10.1016/j.dsx.2020.05.018] [PMID: 32428865]
[38]
Hillaker E, Belfer JJ, Bondici A, Murad H, Dumkow LE. Delayed initiation of remdesivir in a COVID‐19‐positive patient. Pharmacotherapy 2020; 40(6): 592-8.
[http://dx.doi.org/10.1002/phar.2403] [PMID: 32281114]
[39]
Ippolito M, Cortegiani A. Length of remdesivir treatment in patients with severe COVID-19. Breathe (Sheff) 2021; 17(1)200276
[http://dx.doi.org/10.1183/20734735.0276-2020] [PMID: 34295393]
[40]
Helleberg M, Niemann CU, Moestrup KS, et al. Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. J Infect Dis 2020; 222(7): 1103-7.
[http://dx.doi.org/10.1093/infdis/jiaa446] [PMID: 32702095]
[41]
Hoon Baang J, Smith C, Mirabelli C. Prolonged SARS-CoV-2 replication in an immunocompromised patient. J Inf Disp 2020; 223(1): 23-7.
[http://dx.doi.org/10.1093/infdis/jiaa666]
[42]
Zhai G, Li M, Wang Y, Wu J. Drug-induced liver disturbance during the treatment of COVID-19. Front Pharmacol 2021; 12719308
[http://dx.doi.org/10.3389/fphar.2021.719308] [PMID: 34483929]
[43]
Bertolini A, van de Peppel IP, Bodewes FAJA, et al. Abnormal liver function tests in patients with COVID‐19: Relevance and potential pathogenesis. Hepatology 2020; 72(5): 1864-72.
[http://dx.doi.org/10.1002/hep.31480] [PMID: 32702162]
[44]
Soman S, Raveendran AV. Remdesivir and favipiravir for COVID-19: An update. Ann Clin Cardiol 2020; 2(2): 51.
[http://dx.doi.org/10.4103/2666-6979.297511]
[45]
Sabers AJ, Williams AL, Farley TM. Use of remdesivir in the presence of elevated LFTs for the treatment of severe COVID-19 infection. BMJ Case Rep 2020; 13(10)e239210
[http://dx.doi.org/10.1136/bcr-2020-239210] [PMID: 33130588]
[46]
Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. Nat Med 2020; 26(6): 861-8.
[http://dx.doi.org/10.1038/s41591-020-0877-5] [PMID: 32327757]
[47]
LiverTox. Clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases 2012.
[48]
Godeau D, Petit A, Richard I, Roquelaure Y, Descatha A. Return-to-work, disabilities and occupational health in the age of COVID-19. Scand J Work Environ Health 2021; 47(5): 408-9.
[http://dx.doi.org/10.5271/sjweh.3960] [PMID: 34003294]
[49]
Li X, Liu R, Cui Y, et al. Protective effect of remdesivir against pulmonary fibrosis in mice. Front Pharmacol 2021; 12692346
[http://dx.doi.org/10.3389/fphar.2021.692346] [PMID: 34512328]
[50]
Mulangu S, Dodd LE, Davey RT Jr, et al. A Randomized, controlled trial of ebola virus disease therapeutics. N Engl J Med 2019; 381(24): 2293-303.
[http://dx.doi.org/10.1056/NEJMoa1910993] [PMID: 31774950]
[51]
Hopkins BJ, Prokesch BC. Anaphylaxis due to remdesivir. Antimicrob Agents Chemother 2023; 95(5): e00233-21.
[PMID: 33593840]
[52]
Jung SY, Kim MS, Li H, et al. Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database. Clin Transl Sci 2022; 15(2): 501-13.
[http://dx.doi.org/10.1111/cts.13168] [PMID: 34719115]
[53]
Laar SA, Boer MGJ, Gombert-Handoko KB, Guchelaar HJ, Zwaveling J. Liver and kidney function in patients with COVID‐19 treated with remdesivir. Br J Clin Pharmacol 2021; 87(11): 4450-4.
[http://dx.doi.org/10.1111/bcp.14831] [PMID: 33763917]
[54]
Gutierrez R, Mendez-Figueroa H, Biebighauser JG, Bhalwal A, Pineles BL, Chauhan SP. Remdesivir use in pregnancy during the SARS-CoV-2 pandemic. J Matern Fetal Neonatal Med 2022; 35(25): 9445-51.
[http://dx.doi.org/10.1080/14767058.2022.2041595] [PMID: 35168447]
[55]
Deb S, Reeves AA, Hopefl R, Bejusca R. ADME and pharmacokinetic properties of remdesivir: Its drug interaction potential. Pharmaceuticals (Basel) 2021; 14(7): 655.
[http://dx.doi.org/10.3390/ph14070655] [PMID: 34358081]
[56]
Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008; 9(4): 310-22.
[http://dx.doi.org/10.2174/138920008784220664] [PMID: 18473749]
[57]
Plasencia-García BO, Rodríguez-Menéndez G, Rico-Rangel MI, Rubio-García A, Torelló-Iserte J, Crespo-Facorro B. Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review. Psychopharmacology (Berl) 2021; 238(2): 329-40.
[http://dx.doi.org/10.1007/s00213-020-05716-4] [PMID: 33410987]
[58]
Bishara D, Kalafatis C, Taylor D. Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents. Ther Adv Psychopharmacol 2020; 102045125320935306
[http://dx.doi.org/10.1177/2045125320935306] [PMID: 32612804]
[59]
Fan Q, Zhang B, Ma J, Zhang S. Safety profile of the antiviral drug remdesivir: An update. Biomed Pharmacother 2020; 130110532
[http://dx.doi.org/10.1016/j.biopha.2020.110532] [PMID: 32707440]
[60]
Adamsick ML, Gandhi RG, Bidell MR, et al. Remdesivir in patients with acute or chronic kidney disease and COVID-19. J Am Soc Nephrol 2020; 31(7): 1384-6.
[http://dx.doi.org/10.1681/ASN.2020050589] [PMID: 32513665]
[61]
Aiswarya D, Arumugam V, Dineshkumar T, et al. Use of remdesivir in patients with COVID-19 on hemodialysis: A study of safety and tolerance. Kidney Int Rep 2021; 6(3): 586-93.
[http://dx.doi.org/10.1016/j.ekir.2020.12.003] [PMID: 33354635]
[62]
Agarwal A, Chen A, Ravindran N, To C, Thuluvath PJ. Gastrointestinal and liver manifestations of COVID-19. J Clin Exp Hepatol 2020; 10(3): 263-5.
[http://dx.doi.org/10.1016/j.jceh.2020.03.001] [PMID: 32405183]
[63]
Cheng P, Zhu H, Witteles RM, et al. Cardiovascular risks in patients with COVID-19: Potential mechanisms and areas of uncertainty. Curr Cardiol Rep 2020; 22(5): 34.
[http://dx.doi.org/10.1007/s11886-020-01293-2] [PMID: 32350632]
[64]
Martinez-Rojas MA, Vega-Vega O, Bobadilla NA. Is the kidney a target of SARS-CoV-2? Am J Physiol Renal Physiol 2020; 318(6): F1454-62.
[http://dx.doi.org/10.1152/ajprenal.00160.2020] [PMID: 32412303]
[65]
Yatam Ganesh S, Nachimuthu N. Treatment experience with inhaled corticosteroids in combination with remdesivir and dexamethasone among COVID-19 Patients admitted to a rural community hospital: A case series. Cureus 2020; 12(11)e11787
[http://dx.doi.org/10.7759/cureus.11787] [PMID: 33409034]
[66]
Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for COVID-19 - interim WHO solidarity trial results. N Engl J Med 2021; 384(6): 497-511.
[http://dx.doi.org/10.1056/NEJMoa2023184] [PMID: 33264556]
[67]
Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with COVID-19-preliminary report. N Engl J Med 2021; 384(8): 693-704.
[http://dx.doi.org/10.1056/NEJMoa2021436] [PMID: 32678530]
[68]
Benfield T, Bodilsen J, Brieghel C, et al. Improved survival among hospitalized patients with coronavirus disease 2019 (COVID-19) treated with remdesivir and dexamethasone. A nationwide population-based cohort study. Clin Infect Dis 2021; 73(11): 2031-6.
[http://dx.doi.org/10.1093/cid/ciab536] [PMID: 34111274]
[69]
Martinez DR, Schaefer A, Leist SR, et al. Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. Cell Rep 2021; 36(4): 109-450.
[http://dx.doi.org/10.1101/2021.01.27.428478]
[70]
Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med 2021; 384(9): 795-807.
[http://dx.doi.org/10.1056/NEJMoa2031994] [PMID: 33306283]
[71]
Ohl ME, Miller DR, Lund BC, et al. Association of remdesivir treatment with survival and length of hospital stay among US veterans hospi-talized with COVID-19. JAMA Netw Open 2021; 4(7)e2114741
[http://dx.doi.org/10.1001/jamanetworkopen.2021.14741] [PMID: 34264329]
[72]
Dyer O. COVID-19: Remdesivir has little or no impact on survival, WHO trial shows. BMJ 2020; 371: m4057.
[http://dx.doi.org/10.1136/bmj.m4057] [PMID: 33077424]
[73]
Singh S, Khera D, Chugh A, Khera PS, Chugh VK. Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: A systematic review and meta-analysis. BMJ Open 2021; 11(6)e048416
[http://dx.doi.org/10.1136/bmjopen-2020-048416] [PMID: 34168031]
[74]
Siemieniuk RAC, Bartoszko JJ, Zeraatkar D, et al. Drug treatments for COVID-19: Living systematic review and network meta-analysis. BMJ 2020; 370: m2980.
[http://dx.doi.org/10.1136/bmj.m2980] [PMID: 32732190]
[75]
Yang CJ, Wei YJ, Chang HL, et al. Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review. J Microbiol Immunol Infect 2021; 54(1): 27-36.
[http://dx.doi.org/10.1016/j.jmii.2020.09.002] [PMID: 33060041]
[76]
Bansal V, Mahapure KS, Bhurwal A, et al. Mortality benefit of remdesivir in COVID-19: A systematic review and meta-analysis. Front Med (Lausanne) 2021; 7606429
[http://dx.doi.org/10.3389/fmed.2020.606429] [PMID: 33585508]
[77]
Alegre-Del Rey EJ, Gil-Sierra MD, Alarcón de la Lastra-Romero C, Sánchez-Hidalgo M. Remdesivir and mortality reduction in COVID-19 patients: A systematized subgroup analysis of clinical trials. Farm Hosp 2021; 45(1): 28-31.
[PMID: 33443475]
[78]
Olender SA, Perez KK, Go AS, Balani B, Price-Haywood EG, Shah NS, et al. Remdesivir for severe COVID-19 versus a cohort receiving standard of care. Clin Infect Dis 2021; 73(11): e4166-74.
[PMID: 32706859]
[79]
Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial. JAMA 2020; 324(11): 1048-57.
[http://dx.doi.org/10.1001/jama.2020.16349] [PMID: 32821939]
[80]
McCreary EK, Angus DC. Efficacy of remdesivir in COVID-19. JAMA 2020; 324(11): 1041-2.
[http://dx.doi.org/10.1001/jama.2020.16337] [PMID: 32821934]
[81]
Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antibodies and antiviral drugs against COVID-19 omicron variant. N Engl J Med 2022; 386(10): 995-8.
[http://dx.doi.org/10.1056/NEJMc2119407] [PMID: 35081300]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy